Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer

PharmacoEconomics

Volumn 23, Issue 11, 2005, Pages 1155-1166

  Neymark, Niels ^a,g   Lianes, Pilar ^b   Smit, Egbert F ^c,d   Van Meerbeeck, Jan P ^e,f  

^a EORTC DATA CENTER   (Belgium)

^b Medical Oncology ^*  (Spain)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MARTINI HOSPITAL   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g EORTC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH INSURANCE; HUMAN; HYPERSENSITIVITY REACTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COST OF ILLNESS; DEOXYCYTIDINE; HOSPITALIZATION; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES;

EID: 27744500942     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200523110-00007     Document Type: Article

References (25)

1. Lees M, Aristides M, Maniadakis N, et al. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer. Pharmacoeconomics 2002; 20: 325-37
2. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15: 2996-3018
3. Smit EF, van Meerbeeck JPAM, Lianes P, et al. A three-arm randomized study of two cisplatin-based regimens and paclitaxel-gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase III trial of the EORTC Lung Cancer Group (EORTC 08975). J Clin Oncol 2003; 21: 3909-17
4. College Tarieven Gezondheidszorg. Tariefboek medisch specialisten and Bijlage bij Tarieflijst Instellingen 2002 [online]. Available from URL: http://www.ctgzorg.nl [Accessed 2003 Sep]
5. College voor Zorgverzekeringen. Farmakotherapeutisch Kompas 2002. Amstelveen: Medisch Farmaceutische Voorlichting, 2002
6. van Agthoven M, van Inefeld BM, de Boer MF, et al. The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up. Eur J Cancer 2001; 37: 2204-11
7. van Agthoven M, Vellenga E, Fibbe WE, et al. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: a prospective randomized trial. Eur J Cancer 2001; 37: 1781-9100
8. Lau EW, Ng GA. Visual illusions created by survival curves and the need to avoid potential misinterpretation. Med Decis Making 2002; 22: 238-44
9. Karrison TG. Use of Irwin's restricted mean as an index for comparing survival in different groups: interpretation and power considerations. Control Clin Trials 1997; 18: 151-67
10. Neymark N, Adriaenssen I, Gorlia T, et al. Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ 2002; 11: 233-48
11. Neymark N, Gorlia T, Adriaenssen I, et al. Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium. Pharmacoeconomics 2002; 20: 485-97
12. Lin D, Feuer EJ, Ettzioni R, et al. Estimating medical costs from incomplete follow-up data. Biometrics 1997; 53: 419-34
13. Willan AR, Lin DY, Cook RJ, et al. Using inverse-weighting in cost-effectiveness analysis with censored data. Stat Methods Med Res 2002 Dec; 11 (6): 539-51
14. Briggs AH, Mooney CZ, Wonderling DE. Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte-Carlo simulation. Stat Med 1999; 18: 3245-62
15. Gold M, Russell L, Siegel J, et al. Cost effectiveness in health and medicine. Oxford: Oxford University Press, 1996
16. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek. The Netherlands: CVZ Amstelveen, 2000
17. Dranitsaris G, Cottrell W, Evans WK. Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer. Curr Opin Oncol 2002; 14: 375-83
18. Ramsey SD, Mainpour CM, Lovato LC, et al. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. J Natl Cancer Inst 2002; 94: 291-7
19. Waters JS, O'Brien MER. The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of the National Institute of Clinical Excellence (NICE). Br J Cancer 2002; 87: 48-90
20. Plosker GL, Hurst M. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer. Pharmacoeconomics 2001; 19: 1111-34
21. Annemans L, Giaccone G, Vergnenegre A. The cost-effective ness of paclitaxel + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis. Anticancer Drugs 1999; 10: 605-15
22. Gralla RJ, Grusenmeyer PA, Brooks BJ. Evaluating the costs and cost-effectiveness of new regimens for non-small cell lung cancer (NSCLC) [abstract]. 33rd Proc Am Soc Clin Oncol, 1997 May 17; Denver: 420
23. Schiller D, Harrington D, Chandra P, et al. A randomized phase III trial in metastatic NSCLC: an Eastern Co-operative Group trial (ECOG 1594). N Engl J Med 2000; 346: 92-8
24. Berger AM, Clark-Snow RA. Adverse effects of treatment: nausea and vomiting. In: de Vita VT, Hellman S, Rosenberg SA, editors. Cancer: principles & practice of oncology. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2001
25. Sanchez LA, Holdsworth M, Bartel SB. Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis: economic applications. Pharmacoeconomics 2000; 18: 533-56